Meet us at the DGK Conference in April 2025
Venus Medtech is committed to structural heart innovation. Our exceptional heart valve solutions target all four heart valves.
Be sure to join our symposium at DGK to better understand the mechanisms of action of the state-of-art Cardiovalve Replacement System for Tricuspid and Mitral Valve diseases and its current results.
Venus Medtech is committed to structural heart innovation. Our exceptional heart valve solutions target all four heart valves.
Be sure to join our symposium at DGK to better understand the mechanisms of action of the state-of-art Cardiovalve Replacement System for Tricuspid and Mitral Valve diseases and its current results.
MAGNIFY INNOVATION
WITNESS QUALITY:
Attend the session to learn the latest about structural heart intervention
You are welcome to listen to top investigators who will discuss the latest results and future plans for the state-of-art Cardiovalve Replacement System for treating Tricuspid and Mitral Valve diseases.
Join our symposium: April 25th, 17:30-19:00, First Floor, Room 10
Innovation never stops: TTVR in action!
Join this session if you want:
- To understand the anatomical and imaging challenges. associated with transcatheter tricuspid valve replacement
- To gain insights into the latest advances in this rapidly developing clinical field.
- To get an update on current developments in the Cardiovalve tricuspid clinical program.
Chairperson : G. Nickenig
Panel Members: V. Rudolph, M. Adam, M. Weber, F. Kreidel, C. Frerker.
17:30
Session objectives
Georg Nickenig
17:35
The Landscape of Transcatheter Tricuspid Valve Therapies
Volker Rudolph
17:50
TARGET Study : The Latest Clinical Updates
Matti Adam
18:05
TTVR Step-by-Step Live- in- a-Box Case
Marcel Weber
18:20
Challenges in Imaging During TTVR
Felix Kreidel
18:35
TTVr or TTVR? Case-based Discussion
Christian Frerker
18:55
Session Evaluation and Key Learning
Georg Nickenig
Learn more about TARGET
Multicenter Study
Learn more about the TARGET study below.
Multi-center Study
The TARGET Study
Evaluate the safety and performance of the Cardiovalve TR System with its associated procedure in reducing tricuspid regurgitation, signs of TR, and symptoms from TR.
150 participants
A total of 150 subjects will be enrolled. Up to a 5 year follow up.
Up to 50 Medical Center
Centers will be located in North America and Asia
Endpoints
Symptomatic subjects (NYHA Class ≥ II-IVa) with at least severe tricuspid regurgitation (≥3+ in a 5-tier grading) requiring valve replacement or repair who are at high risk for open chest surgery according to the Heart Team decision and approved by the Subject Screening Committee.
Innovation Never Stops!